GPCR-Based Drug Discovery


Cambridge Healthtech Institute 第12届
GPCR为基础的新药发现
新标靶Class的方法与新药剂候补

第15届Discovery on Target其中一环

本会议思考重视标靶的新时代新药发现,将介绍应用G蛋白质偶联受体 (GPCR) 结构与构型相关知识,实现偏倚受体朝合适的途径传达讯号并避免经不好的途径的新药剂候补调整方法。另外也将讨论贯通细胞膜的复杂标靶Class的GPCR标靶化,分享目前研究成果、检讨各种GPCR结构研究重要成果及生物物理学技术应用对GPCR为基础的新药发现之影响。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Constrained Peptides and Macrocyclics

· September 25 Short Course: GPCR Structure-Based Drug Discovery

· September 26-27 Conference: GPCR-Based Drug Discovery

· September 27-28 Conference: Antibodies Against Membrane Protein Targets - Part 2: Structural Analysis, Characterization and Biopharmaceutical Development

· September 27 Short Course: Introduction to Allosteric Modulators and Biased Ligands of GPCRs

· September 28-29 Symposium: CNS and Neurodegenerative Targets


Tuesday, September 26

7:00 am Registration Open and Morning Coffee

GPCR Pharmacology and Biased Signaling

8:00 Welcome Remarks

Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute

8:05 Chairperson's Opening Remarks

Annette Gilchrist, Ph.D., Professor, Pharmacology, Midwestern University

8:10 Mechanistic Insights into Opioid Receptor Function from Molecular Dynamics Simulations

FEATURED PRESENTATION: Marta Filizola, Ph.D., Professor, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai

Understanding at the molecular level how to fine-tune opioid receptor signaling toward the analgesic pathway and away from those mediating adverse effects is essential for the future discovery of improved opioid-based painkillers for the management of acute and/or chronic pain. I will provide an overview of studies we are carrying out to address this problem using enhanced molecular dynamics simulation strategies and cutting-edge statistical analyses.

8:40 Biased Signaling at µ Opioid Receptor Splice Variants

Ying-Xian Pan, M.D., Ph.D., Laboratory Head, Department of Neurology, Memorial Sloan Kettering Cancer Center

Extensive 3' alternative splicing of the µ opioid receptor gene (OPRM1) creates multiple C-terminal splice variants that are potentially subjected to biased signaling. We now demonstrate in vitro that several µ agonists display differential β-arrestin 2 or G protein bias against a number of Oprm1 C-terminal splice variants, which correlates with in vivo data using targeted mouse models, providing new insights on GPCR-biased signaling.

9:10 High Resolution Crystal Structure of the Apelin Receptor

Liaoyuan Hu, Ph.D., Scientific Director, Head of Pharmacology, Amgen Asia R&D Center

The apelin receptor (APJ) plays an important role in a wide range of physiological functions and is a potential target for the treatment of a variety diseases. Here we report the high resolution co-crystal structure of APJ in complex with a surrogate peptide agonist. Overall structural features of the complex and detailed peptide/receptor interactions will be discussed.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

GPCR Pharmacology and Biased Signaling (Cont.)

10:25 Ozanimod: An S1P1,5R Modulator that Causes Receptor Internalization Resulting in Altered Lymphocyte Trafficking and Amelioration of Inflammation

Julie Selkirk, Ph.D., Associate Director of Biology, Receptos/Celgene

S1P1R is a GPCR expressed on lymphocytes mediating migration out of secondary lymphoid tissues. S1P1R modulators internalize the receptor, sequestering lymphocytes and preventing their migration to inflammation sites. The S1P1,5R modulator ozanimod is in clinical development to treat Multiple Sclerosis and Inflammatory Bowel Disease. This presentation will cover the pharmacological tools we used to identify a safe and effective S1P1,5R modulator and evidence that ozanimod utilizes different residues than FTY720-p in the orthosteric ligand binding pocket.

10:55 Structure of a Family A GPCR with Synthetic Ligands Bound

Adam Weinglass, Ph.D., Director, Screening & Compound Profiling, Merck & Co.

Agonists of GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus. Pharmacologic studies indicate that partial and full allosteric agonists (AgoPAMs) bind distinct sites on GPR40 eliciting differentiated preclinical efficacy. Here, we present the path to a ternary complex structure with partial and full allosteric agonists bound, and evidence supporting an identified novel, lipid-facing AgoPAM binding pocket.

11:25 Biased and Cell-Specific Agonists of the Heart Disease Target, RXFP1, a Peptide-Targeted GPCR

Ross Bathgate, Ph.D., Head, Neuropeptides Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne

This presentation will discuss peptide mimetic and small molecule development at a complex peptide GPCR, the heart disease target, RXFP1. We have developed a relaxin peptide mimetic with a cell-specific signaling profile and demonstrated that an RXFP1 small molecule agonist is an allosteric biased agonist. This highlights the need to screen GPCR targeted small molecules or biologics in relevant native cell systems for biased and cell-specific signaling.

11:55 Imipridones: A New Class of Anti-Cancer Small Molecules that Selectively Engage GPCRs

Varun Prabhu, Ph.D., Associate Director, Research & Development, Oncoceutics, Inc.

GPCRs are the most commonly exploited target in modern medicine; however, efforts in oncology have been limited. We describe imipridone small molecules with a unique tri-heterocyclic core structure that selectively target GPCRs. Lead candidates were profiled using the DiscoverX GPCR platform and characterized for mechanism of action and anti-cancer efficacy.

12:10 pm Sponsored Presentation (Opportunity Available)

12:25 Session Break

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

GPCRs in Cancer and Other Diseases

1:50 Chairperson's Remarks

Sid Topiol, Ph.D., CSO, 3D-2drug, LLC; Professor and Director, Structural and Computational Drug Discovery, Stevens Institute of Technology

1:55 GPCRs in Immune Evasion of Cancer

Tillmann Michels, Ph.D., Head of Research Group Immune Checkpoint Inhibitors, Laboratory of Phillipp Beckhove, Interventional Immunology, Regensburg Center for Interventional Immunology

Checkpoint blockade has become an important pillar of cancer therapy. We identified GPCRs and their associated signaling as immune inhibitory pathways using high throughput RNAi screening. GPCRs could either affect T cell activity directly by binding or indirectly by altering the balance of tumor-intrinsic Gα signaling. For example, cAMP can be transported into TILs and induce an inhibitory pathway resulting in TCR-associated Lck inhibition.

2:25 Phenotypic Discovery of ONC201 as the First Selective DRD2 Antagonist for Clinical Oncology

Joshua Allen, Ph.D., Vice President, R&D, Oncoceutics

Imipridones are a new class of anti-cancer small molecules that share a unique tri-heterocyclic core structure and selectively engage GPCRs. Experimental GPCR profiling revealed imipridone ONC212 selectively targets orphan GPCR GPR132/G2A at nanomolar concentrations. GPR132 is a stress-inducible orphan GPCR with highest expression in leukemia and shown to be a tumor suppressor in the context of lymphoid leukemogenesis. ONC212 was non-toxic to normal cells at therapeutic concentrations and demonstrated robust in vivo safety/efficacy in leukemia xenograft

2:55 Present and Future Collaborative Innovations within Drug Discovery Informatics

Charlie Weatherall, Director, Customer Engagement, Collaborative Drug Discovery

The CDD Vault platform (Activity & Registration, Visualization, Inventory, & ELN) provides an easy, secure way for the collaborative sharing of research data and workflows. Web-based platforms are a natural fit for collaborations due to the economic and design benefits of a single platform that transcends any one organization's requirements.

3:10 3DM Protein-Family Analysis Platform Applied to the GPCR Protein-Family

Henk-Jan Joosten, Ph.D., CEO, Bio-Prodict

Vast amounts of data are available for protein-families (e.g., sequences, literature, structural-, alignment-, SNP-, mutation-, patent-, binding data). 3DM, a protein-superfamily analysis platform, automatically collects and integrates all data and contains many state-of-the-art analysis tools. 3DM is used by many companies, including large pharma, to guide structure-based drug design.

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

GPCRs in Cancer and Other Diseases (Cont.)

4:05 The Apelin Receptor: Modulating Ligand Structure to Bias Signaling and Impacts on Acute Cardiac Dysfunction

Eric Marsault, University of Sherbrooke

4:35 Development of GIP Receptor Antagonists to Reveal the Role of GIP in Physiology and Pathophysiological Conditions Like Obesity and T2D

Mette M. Rosenkilde, M.D., Ph.D., Professor, Department of Biomedical Sciences, University of Copenhagen

I will discuss the incretins (that bind to class B GPCRs) and novel data for the production of a GIPR (glucose-dependent insulinotropic polypeptide receptor) antagonist for the treatment of T2D and obesity. I will also compare the action of GIP with that of the other famous incretin hormone, GLP1, for which several therapies have been launched recently.

5:05 Interactive Breakout Discussion Groups

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)

7:10 Close of Day

Wednesday, September 27

7:30 am Registration Open and Morning Coffee

Structural And Biophysical Approaches For GPCRs

8:00 Chairperson's Remarks

Andrew Alt, Ph.D., Associate Director, Biology, Arvinas

8:05 Crystal Structure of the GLP-1 Receptor Extracellular Domain in Complex with Exendin-4 and a Nanobody

Xiaomin Chen, Ph.D., Senior Principal Scientist, Structural & Molecular Sciences, Worldwide Research & Development, Pfizer

Glucagon-like peptide 1 receptor is one of the class B GPCR and an important drug target. It has an extracellular domain (ECD) in addition to the seven-transmembrane helices and the primary role of the ECD is to bind to a peptide ligand to position it so that its N-terminus binds to the transmembrane region for its activation. Here we report the crystal structure of the receptor ECD bound to exendin-4 and a nanobody.

8:35 Picking the High-Hanging Fruit: Measuring Biomolecular Interactions of GPCRs Using a Variety of Biophysical Techniques

Phillip Schwartz, Ph.D., Senior Scientist, Structural Biology and Biophysics, Takeda California

Drug discovery efforts are undergoing a renaissance in GPCR-related research as orphan receptors become de-masked and our understanding of how to study these difficult targets improves. Identifying preparations amenable to biophysical characterization is a critical step in pursuing GPCR drug development.

9:05 Presentation to be Announced


9:35 Coffee Break in the Exhibit Hall with Poster Viewing

Structural and Biophysical Approaches for GPCRs (Cont.)

10:20 NMR Spectroscopy and Integrative Structural Biology of Human GPCRs

Matthew Eddy, Ph.D., Postdoctoral Fellow, Laboratory of Raymond Stevens, The Bridge Institute, University of Southern California

Nuclear magnetic resonance (NMR) spectroscopy complements other structural biology techniques, such as x-ray diffraction, by identifying multiple simultaneously populated conformations in equilibrium. Here, we leverage this advantage to study two human GPCRs. First, we report how a GPCR fusion strategy used for x-ray crystallography influences the protein conformational equilibrium and highlight potential cases where drug-ligand interactions can be affected. Second, we report a novel approach to incorporation of stable isotopic NMR labels into a wild type human GPCR and new insights obtained from this method.

10:50 Next Generation Bio-Sensing: New Opportunities for Challenging Targets
Tim Kaminski, Ph.D., Postdoctoral Fellow, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca Gothenburg
Single molecule experiments enable us, next to its unmatched sensitivity, to directly gain a mechanistic insight into biological processes by observing its stochastic behavior. We are developing a toolbox which advances single molecule microscopy from a method primarily used in academia into a versatile tool for drug discovery. By using this method, we are able to address shortcomings of established biophysical methods as e.g. tight binding limit, working with membrane proteins, higher throughput. Additionally, we are able to extract kinetic profiling of inhibition reactions in solution by observing the association and dissociation of thousands of molecules in parallel with a surface-based single molecule platform.

11:20 Enjoy Lunch on Your Own

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

2:45 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

目录下载
Catalog


Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务